Shandong Jincheng Pharmaceutical Group Co., Ltd
300233.SZ · SHZ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | CN¥3,373 | CN¥3,538 | CN¥3,506 | CN¥3,138 |
| % Growth | -4.7% | 0.9% | 11.7% | – |
| Cost of Goods Sold | CN¥2,020 | CN¥2,073 | CN¥1,885 | CN¥1,487 |
| Gross Profit | CN¥1,354 | CN¥1,465 | CN¥1,620 | CN¥1,651 |
| % Margin | 40.1% | 41.4% | 46.2% | 52.6% |
| R&D Expenses | CN¥170 | CN¥185 | CN¥171 | CN¥178 |
| G&A Expenses | CN¥346 | CN¥71 | CN¥368 | CN¥340 |
| SG&A Expenses | CN¥789 | CN¥695 | CN¥996 | CN¥1,164 |
| Sales & Mktg Exp. | CN¥443 | CN¥624 | CN¥629 | CN¥828 |
| Other Operating Expenses | -CN¥19 | CN¥17 | CN¥372 | CN¥344 |
| Operating Expenses | CN¥941 | CN¥1,239 | CN¥1,214 | CN¥1,387 |
| Operating Income | CN¥267 | CN¥226 | CN¥354 | CN¥210 |
| % Margin | 7.9% | 6.4% | 10.1% | 6.7% |
| Other Income/Exp. Net | CN¥1 | -CN¥0 | -CN¥8 | -CN¥14 |
| Pre-Tax Income | CN¥268 | CN¥225 | CN¥346 | CN¥197 |
| Tax Expense | CN¥61 | CN¥32 | CN¥60 | CN¥73 |
| Net Income | CN¥197 | CN¥175 | CN¥273 | CN¥108 |
| % Margin | 5.8% | 4.9% | 7.8% | 3.4% |
| EPS | 0.52 | 0.46 | 0.71 | 0.28 |
| % Growth | 13% | -35.2% | 153.6% | – |
| EPS Diluted | 0.52 | 0.46 | 0.71 | 0.28 |
| Weighted Avg Shares Out | 379 | 384 | 385 | 386 |
| Weighted Avg Shares Out Dil | 379 | 384 | 385 | 386 |
| Supplemental Information | – | – | – | – |
| Interest Income | CN¥13 | CN¥15 | CN¥12 | CN¥12 |
| Interest Expense | CN¥20 | CN¥26 | CN¥28 | CN¥28 |
| Depreciation & Amortization | CN¥319 | CN¥312 | CN¥259 | CN¥224 |
| EBITDA | CN¥606 | CN¥564 | CN¥629 | CN¥448 |
| % Margin | 18% | 15.9% | 17.9% | 14.3% |